InflaRx N.V.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- InflaRx N.V. (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting the complement system for treating life-threatening inflammatory diseases. The company offers a pipeline of product candidates including gozetimide (IFX-1), a first-in-class anti-human complement factor C5a monoclonal antibody for indications such as hidradenitis suppurativa (HS), pyoderma gangrenosum (PG), ANCA-associated vasculitis (AAV), and other inflammatory conditions; INF904, an orally administered small molecule C5a receptor inhibitor for potential use in chronic obstructive pulmonary disease (COPD), bronchiectasis, and dermatological disorders; and earlier-stage assets like IFX002 and other complement inhibitors. InflaRx operates primarily in the biotechnology sector, serving patients and healthcare providers through clinical trials and regulatory pathways in North America, Europe, and select international markets, with headquarters in Jena, Germany, and was founded in 2007. Recent developments include the advancement of gozetimide into Phase 3 trials for HS following positive Phase 2 results, expansion of the INF904 program with new preclinical data presented at medical conferences in 2024-2025, and strategic collaborations with entities like Boehringer Ingelheim for complement research synergies, alongside ongoing fundraising efforts through equity offerings to support pipeline progression amid no major acquisitions or name changes reported in the last two years.
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
InflaRx to Report First Quarter 2026 Results on May 7, 2026
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
InflaRx N.V. (NASDAQ:IFRX) Receives $6.17 Consensus PT from Analysts
Reviewing Athira Pharma (NASDAQ:ATHA) & InflaRx (NASDAQ:IFRX)
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
InflaRx to Report Full Year 2025 Results on March 19, 2026
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference